Author

Yanzhi Feng

Yale University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetics· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1

Frequent Co-Authors

Chuanpeng DongiD· 2 shared Nipun VermaiD· 2 shared Ping ReniD· 2 shared Shan XiniD· 2 shared Sidi CheniD· 2 shared Binfan Chen· 1 shared Bo Tao· 1 shared Chuan Liu· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Chuanpeng DongORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CAR-T-drug conjugate against solid tumor

Shan Xin, Yanzhi Feng, Feifei Zhang, Jiang Yu, Chuanpeng Dong, Bo Tao, Kaiyuan Tang, Qihao Wu, Binfan Chen, Ping Ren, Nipun Verma, Chuan Liu, Kazushi Suzuki, Xinyu Ling, Daniel Park, , Sidi Chen

This paper introduces CAR-T-drug conjugates (CAR-T-D-C) to improve CAR-T therapy for solid tumors by combining chemotherapy with CAR-T cells, enhancing tumor infiltration and immune response.

bioRxiv · Jan 2, 2026 · PreprintImmunology

Genome scale CRISPR screens identify actin capping proteins as key modulators of therapeutic responses to radiation and immunotherapy

Xin Shan, Paul A. Renauer, Chuanpeng Dong, Yanzhi Feng, Ping Ren, Qianqian Lin, Feifei Zhang, Narges Tafreshi, Peter M. Glazer, Sidi Chen, Nipun Verma

The paper identifies actin capping proteins as key modulators of therapeutic responses to radiation and immunotherapy through genome-scale CRISPR screens in melanoma cells.

bioRxiv · Jan 14, 2024 · PreprintGenetics